Sun Pharma and IDFC First Bank Report Strong Q3FY26 Earnings

Sun Pharmaceutical Industries Ltd. reported a 16% year-on-year increase in net profit to ₹3,368.8 crore for the third quarter of FY26, up from ₹2,903 crore in the same period last year. Revenue from operations rose by 13.5% to ₹15,520.5 crore. The company's board declared an interim dividend of ₹11 per equity share, with a record date of February 5, 2026, and payment scheduled on or before February 16, 2026.

IDFC First Bank announced a 48% year-on-year rise in net profit to ₹503 crore for the third quarter of FY26, compared to ₹339 crore in the corresponding quarter of the previous fiscal year. Total income increased to ₹12,542 crore from ₹11,123 crore, while net interest income grew to ₹5,492 crore from ₹4,902 crore. The bank's gross non-performing assets ratio improved to 1.69% from 1.94% a year ago.